You are here: Industry Insights > melanoma

News List

Calculated Tumor Area Has Prognostic Value for Melanoma drugs
July 02, 2019
Calculated Tumor Area Has Prognostic Value for Melanoma.
No Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in Blood drugs
June 13, 2019
Laser-Based Test Hunts Stray Melanoma Cells in Blood.
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® worldpharmanews
June 10, 2019
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®.
Rare melanoma type highly responsive to immunotherapy europeanpharmaceuticalreview
April 30, 2019
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Repurposing leukaemia drugs may prevent melanoma metastasis europeanpharmaceuticalreview
April 25, 2019
Data from a new study shows that repurposing drugs used to treat leukaemia has promise for preventing melanoma metastasis…
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma drugs
April 17, 2019
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma.
AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial americanpharmaceuticalreview
February 26, 2019
AIVITA Biomedical announced its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial.....
Keytruda gets okay from FDA for adjuvant melanoma pharmaphorum
February 21, 2019
The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes.
Sanofi announces myeloma drug meets primary endpoint pharmaceutical-technology
February 19, 2019
French pharma giant Sanofi has unveiled that its multiple myeloma drug isatuximab has met its primary endpoint of prolonged progression-free survival in a Phase III trial.....
Novartis to divest Proleukin’s US rights to Clinigen for $210m pharmaceutical-technology
February 14, 2019
Novartis has signed an agreement to divest the US rights to its Proleukin (aldesleukin) medicine to UK-based Clinigen Group for a total cash consideration of up to $210m.....

Previous page 1 2 3 4 5 6 7 Next page